AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the discovery, development, and commercialization of various bacteriophage therapeutics. Its lead product candidate comprises AB-SA01 that is in Phase I clinical trial for the treatment of Staphylococcus aureus (S. aureus) infections, including methicillin-resistant S. aureus. The company's products under development include AB-PA01 for the treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients; and AB-CD01 for the treatment of Clostridium difficile infections. It has a collaboration agreement with Intrexon Corporation to utilize synthetic biology platform for the identification, development, and production of bacteriophage-containing human therapeutics. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is based in San Diego, California.